A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, January 4, 2016
Higher-dose portions of multiple-sclerosis studies with Laquinimod drug terminated
Teva Pharmaceutical Industries Ltd. and Active Biotech AB said Monday they were ending the higher-dose portions of two multiple-sclerosis studies with the drug Laquinimod after eight patients suffered nonfatal cardiovascular events.
The companies said the incidents occurred in the higher-dose components of a phase 3 and a phase 2 clinical trial. The lower-dose and placebo components of the tests will continue.
Phase 3 clinical trials are typically the last phase before a drug gets approval from the U.S. Food and Drug Administration.
Laquinimod is a once-daily oral drug being developed for treating multiple sclerosis and Huntington disease.